Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Sponsor: Epizyme, Inc.
Terminated
FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns
Other terminated trials from Epizyme, Inc.
- T-cell Lymphoma · Mar 2026
- Advanced Malignant Solid Tumor · Mar 2025
- Metastatic Castration-resistant Prostate Cancer · Phase PHASE1/PHASE2 · Nov 2024
- Diffuse Large B Cell Lymphoma Refractory · Phase PHASE1 · Apr 2024
- Head and Neck Squamous Cell Carcinoma · Phase PHASE1 · Feb 2024
More terminations from Epizyme, Inc.
This PHASE1 trial investigates Advanced Epithelioid Sarcoma and Advanced Soft-tissue Sarcoma and is currently terminated or withdrawn. Epizyme, Inc. leads this study, which shows 30 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
30 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
Phase: PHASE3 → PHASE1
-
Sep 2025 — Feb 2026 [monthly]
Terminated PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
▶ Show 25 earlier versions
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Mar 2022 — Mar 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Feb 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Epizyme, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .